Virgilio Deloy Capobian Gibbon Sells 20,900 Shares of Afya (NASDAQ:AFYA) Stock

Afya Limited (NASDAQ:AFYA) CEO Virgilio Deloy Capobian Gibbon sold 20,900 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $14.94, for a total value of $312,246.00. Following the completion of the sale, the chief executive officer owned 109,218 shares in the company, valued at $1,631,716.92. This trade represents a 16.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Virgilio Deloy Capobian Gibbon also recently made the following trade(s):

• On Monday, April 6th, Virgilio Deloy Capobian Gibbon sold 770 shares of Afya stock. The shares were sold at an average price of $14.91, for a total value of $11,480.70.
• On Wednesday, April 1st, Virgilio Deloy Capobian Gibbon sold 19,500 shares of Afya stock. The shares were sold at an average price of $14.98, for a total value of $292,110.00.
• On Tuesday, March 31st, Virgilio Deloy Capobian Gibbon sold 2,320 shares of Afya stock. The shares were sold at an average price of $14.92, for a total value of $34,614.40.
• On Thursday, March 26th, Virgilio Deloy Capobian Gibbon sold 800 shares of Afya stock. The shares were sold at an average price of $15.21, for a total value of $12,168.00.
• On Wednesday, March 25th, Virgilio Deloy Capobian Gibbon sold 3,900 shares of Afya stock. The shares were sold at an average price of $15.18, for a total value of $59,202.00.

Afya Trading Up 0.2%

Shares of Afya stock traded up $0.03 on Monday, hitting $14.99. 197,630 shares of the company’s stock traded hands, compared to its average volume of 113,194. Afya Limited has a one year low of $13.00 and a one year high of $19.90. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.20 and a quick ratio of 0.98. The company has a fifty day moving average of $14.48 and a two-hundred day moving average of $14.70. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of 10.27, a price-to-earnings-growth ratio of 0.67 and a beta of 0.48.

Afya (NASDAQ:AFYA) last announced its quarterly earnings results on Wednesday, March 11th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.05. The business had revenue of $147.08 million for the quarter, compared to analyst estimates of $174.74 million. Afya had a return on equity of 18.77% and a net margin of 20.31%. As a group, sell-side analysts expect that Afya Limited will post 1.52 earnings per share for the current year.

Afya Dividend Announcement

The business also recently disclosed an annual dividend, which will be paid on Monday, April 6th. Stockholders of record on Wednesday, March 25th will be paid a $0.656 dividend. The ex-dividend date of this dividend is Wednesday, March 25th. This represents a dividend yield of 433.0%. Afya’s dividend payout ratio is 45.21%.

Hedge Funds Weigh In On Afya

A number of large investors have recently made changes to their positions in AFYA. Doma Perpetual Capital Management LLC boosted its holdings in shares of Afya by 50.6% in the third quarter. Doma Perpetual Capital Management LLC now owns 891,639 shares of the company’s stock worth $13,910,000 after acquiring an additional 299,419 shares during the period. SPX Gestao de Recursos Ltda bought a new position in shares of Afya in the third quarter worth $2,895,000. Swedbank AB boosted its holdings in shares of Afya by 170.3% in the fourth quarter. Swedbank AB now owns 189,200 shares of the company’s stock worth $2,916,000 after acquiring an additional 119,200 shares during the period. Jump Financial LLC bought a new position in shares of Afya in the second quarter worth $731,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Afya in the third quarter worth $610,000. 88.02% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. UBS Group reaffirmed a “neutral” rating and set a $16.00 price target (down from $18.00) on shares of Afya in a research report on Friday, January 16th. Bank of America downgraded Afya from a “buy” rating to a “neutral” rating and decreased their price target for the company from $22.00 to $17.00 in a research report on Tuesday, February 24th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $22.00 price target (down from $24.50) on shares of Afya in a research report on Wednesday, January 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Afya in a research report on Wednesday, January 21st. Finally, Wall Street Zen raised Afya from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 14th. One analyst has rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $17.30.

About Afya

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.